Due to recent safety concerns with beta 2 adrenoceptor agonists (e.g. salbutamol), there has been an ongoing attempt to identify novel bronchodilator agents for use in asthma and COPD. Due to its beneficial action on airway calibre, prostaglandin E 2 (PGE 2 ) was previously investigated as a potential therapy, however in addition to bronchodilator activity, in clinical studies PGE 2 also produced tussive effects and bronchial irritancy. As PGE 2 mediates its actions via a number of different prostanoid receptors, it was hoped that by selectively targeting individual receptors, the beneficial actions could be selected. In a previous study (Nials et al 1993), the EP 2 receptor was identified as mediating PGE 2 -induced relaxation however when tested clinically, an EP 2 agonist (AH13205) produced disappointing results.
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To investigate the receptor involved in PGE 2 -induced airway smooth muscle relaxation, isolated tracheal tissue from a number of species (guinea pig, mouse, rat, Cyno monkey, human) was sutured to forcedisplacement transducers (Grass Instruments, U.S.A.) in 10ml organ baths containing 10µM indomethacintreated Kreb's Henseleit solution heated to 37˚C and bubbled with 95% O 2 /5% CO 2 . Contractile tone was induced using 1µM carbachol and selective prostanoid receptor agonists and antagonists were evaluated. In addition, the relaxation to PGE 2 was investigated in tracheal segments from prostanoid receptor deficient mice.
The data produced showed that in guinea pig, mouse and Cyno monkey tracheal tissue, PGE 2 -induced relaxation is mediated by EP 2 receptors. However in rat and human tissue, the EP 4 receptor appears to mediate PGE 2 induced relaxation. The two EP 2 agonists tested failed to relax human airway samples and 10µM AH6809 (an EP 1 /EP 2 /DP selective antagonist) failed to inhibit PGE 2 -induced relaxation. Conversely, the EP 4 agonist ONO-AE1-329 produced substantial relaxation (76.2 ± 8.6% max relaxation to 100µM papaverine) and two structurally different EP 4 antagonists GW627368X and ONO-AE3-208 (both 1µM) both inhibited PGE 2 -induced relaxation.
These results therefore offer a potential explanation for the poor efficacy of the EP 2 agonist (AH13205) in human subjects. In contrast to guinea pig tissue (where AH13205 produced the expected relaxant response), the EP 4 receptor mediates PGE 2 -induced relaxation in human airways. Furthermore, as we have recently (Maher et al 2009) identified the EP 3 receptor as mediating the tussive actions of PGE 2 , it appears possible that an EP 4 agonist could potentially produce the beneficial actions of PGE 2 in the absence of bronchial irritation or tussive effects. If this data is paralleled in clinical studies, targeting the EP 4 receptor could produce the most promising novel bronchodilator for several decades.
